Xue Hu

Targeting EP2 overcomes osimertinib-tolerant persisters through metabolic and inflammatory reprogramming in non-small cell lung cancer.

Although osimertinib is an effective third-generation EGFR inhibitor for EGFR-mutant NSCLC, the emergence of acquired resistance continues to limit its long-term clinical benefit. However, the early cellular adaptations that allow residual tumor cells to survive osimertinib exposure are not fully understood. Here, we c...